title: Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.
abstract: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease that great efforts had been made in to build up molecular and immunophenotypic subgroups that could relatively accurate indicate prognosis and give clue to therapy. Recently, CD30 was reported as a useful predictor with favorable clinical outcome. However, CD30 expression patterns and the clinicopathologic features of CD30 positive DLBCL are not well described thus far, especially in Asian patients. Here, we studied 232 cases of de novo DLBCL in East China to investigate the prevalence and clinicopathological features of CD30-positive DLBCL using a panel of immunohistochemical markers. Applying a >0% threshold, CD30 was expressed in approximately 12% patients with Epstein-Barr virus (EBV) negative DLBCL, affecting younger people and showing a lower frequency of BCL2 expression and MYC/BCL2 co-expression. Patients with CD30-positive DLBCLs showed better progression-free survival and overall survival compared with patients with CD30-negative DLBCLs, although the superior outcome of CD30 positivity had minimal effects on BCL2+ DLBCL or DLBCL with MYC/BCL2 co-expression. Moreover, CD30 could express in CD5+ DLBCL. We concluded that CD30 may be useful as a prognostic marker in rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treated DLBCLs, indicating favorable outcomes in a Chinese population. Further studies with larger samples should be performed to investigate the function of CD30 expression in BCL2+ DLBCLs, DLBCLs with MYC/BCL2 co-expression, and CD5+ DLBCLs, and to evaluate the feasibility of anti-CD30 targeted treatment in DLBCL therapy.
authors.affiliation: Department of Pathology, the First Affiliated Hospital of Nanjing Medical UniversityNanjing, China; Department of Pathophysiology, Nanjing Medical UniversityNanjing, China.
authors.forename: Qi-Xing
authors.initials: QX
authors.lastname: Gong
authors.affiliation: Department of Hematology, the First Affiliated Hospital of Nanjing Medical UniversityNanjing, China; Department of Oncology, Affiliated Hospital of Jiangnan UniversityWuxi, Jiangsu Province, China.
authors.forename: Ting-Xun
authors.initials: TX
authors.lastname: Lu
authors.affiliation: Department of Pathology, the First Affiliated Hospital of Nanjing Medical University Nanjing, China.
authors.forename: Chong
authors.initials: C
authors.lastname: Liu
authors.affiliation: Department of Pathology, the First Affiliated Hospital of Nanjing Medical University Nanjing, China.
authors.forename: Zhen
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Department of Hematology, the First Affiliated Hospital of Nanjing Medical University Nanjing, China.
authors.forename: Jin-Hua
authors.initials: JH
authors.lastname: Liang
authors.affiliation: Department of Hematology, the First Affiliated Hospital of Nanjing Medical University Nanjing, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Xu
authors.affiliation: Department of Hematology, the First Affiliated Hospital of Nanjing Medical University Nanjing, China.
authors.forename: Jian-Yong
authors.initials: JY
authors.lastname: Li
authors.affiliation: Department of Pathology, the First Affiliated Hospital of Nanjing Medical University Nanjing, China.
authors.forename: Zhi-Hong
authors.initials: ZH
authors.lastname: Zhang
authors.affiliation: Department of Pathophysiology, Nanjing Medical University Nanjing, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D044466:Asian People; D014408:Biomarkers, Tumor / Q000032:analysis*; D018956:CD5 Antigens / Q000032:analysis; D002681:China; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D017730:Ki-1 Antigen / Q000032:analysis*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000737:chemistry* / Q000188:drug therapy / Q000208:ethnology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011241:Prednisone / Q000627:therapeutic use; D015995:Prevalence; D019253:Proto-Oncogene Proteins c-bcl-2; D016271:Proto-Oncogene Proteins c-myc; D012189:Retrospective Studies; D012307:Risk Factors; D000069283:Rituximab; D013997:Time Factors; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C000595707:BCL2 protein, human; D014408:Biomarkers, Tumor; D018956:CD5 Antigens; D017730:Ki-1 Antigen; C489427:MYC protein, human; D019253:Proto-Oncogene Proteins c-bcl-2; D016271:Proto-Oncogene Proteins c-myc; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: CD30; CD5+ DLBCL; Diffuse large B-cell lymphoma; MYC/BCL2 co-expression lymphoma